Orexo's patent win for ZUBSOLV® appealed
UPPSALA, Sweden, July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
- Supported exchanges /
- F /
- C5G.F
Orexo AB (publ) (C5G F) stock market data APIs
€0.879
-0.03(-3.3%)
as of November 1, 2024
Price chart is built with Anychart
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ) Financial Data Overview
| 0.909 | |
| 0.879 | |
| - | |
| 0.91 | |
| 0.879 | |
| 0.879-2.02 | |
| 34 762 K | |
| 34 450 K | |
| 596 M | |
| 0.566 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'C5G',
Type:
'Common Stock',
Name:
'Orexo AB (publ)',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
'SE0000736415',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
}
Orexo AB (publ) Fundamental Data is available in our Financial Data APIs
- Net Revenue 596 M
- EBITDA 67 800 K
- Earnings Per Share -0.26
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Orexo AB (publ) Earnings via APIs
- Latest Release 2024-10-24
- EPS/Forecast NaN
Get Orexo AB (publ) End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Orexo AB (publ) latest news via APIs
Orexo Q2 2023 Interim Report
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › EBITDA of SEK 5....
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
